Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells
Yi-Bin Chen, Jennifer Le-Rademacher, Ruta Brazauskas, Deidre M Kiefer, Mehdi Hamadani, John F DiPersio, Mark R Litzow, Michael Craig, Mitchell E Horwitz, Andrew S Artz, Brian L McClune, Hugo F Fernandez, Hien Kim Duong, Hati Kobusingye, Mandi Proue, Rebecca J Drexler, Mary M Horowitz, Bronwen E Shaw, John P Miller, Sakura Hosoba, Edmund K Waller, Steven M Devine, Yi-Bin Chen, Jennifer Le-Rademacher, Ruta Brazauskas, Deidre M Kiefer, Mehdi Hamadani, John F DiPersio, Mark R Litzow, Michael Craig, Mitchell E Horwitz, Andrew S Artz, Brian L McClune, Hugo F Fernandez, Hien Kim Duong, Hati Kobusingye, Mandi Proue, Rebecca J Drexler, Mary M Horowitz, Bronwen E Shaw, John P Miller, Sakura Hosoba, Edmund K Waller, Steven M Devine
Abstract
Plerixafor, a direct antagonist of CXCR4/stromal-derived factor 1, can safely and rapidly mobilize allografts without the use of granulocyte colony-stimulating factor (G-CSF). We conducted a phase 2, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts for allogeneic hematopoietic cell transplantation in recipients with hematological malignancies. Donors (n = 64) were treated with subcutaneous plerixafor (240 µg/kg) and started leukapheresis (LP) 4 hours later. The primary objective was to determine the proportion of donors who were successfully mobilized: defined as collection of ≥2.0 × 106 CD34+ cells per kilogram recipient weight in ≤2 LP sessions. Recipients subsequently received reduced intensity (RIC; n = 33) or myeloablative (MAC; n = 30) conditioning. Sixty-three of 64 (98%) donors achieved the primary objective. The median CD34+ cell dose per kilogram recipient weight collected within 2 days was 4.7 (0.9-9.6). Plerixafor was well tolerated with only grade 1 or 2 drug-related adverse events noted. Bone pain was not observed. Plerixafor-mobilized grafts engrafted promptly. One-year progression-free and overall survivals were 53% (95% confidence interval [CI], 36% to 71%) and 63% (95% CI, 46% to 79%) for MAC and 64% (95% CI, 47% to 79%) and 70% (95% CI, 53% to 84%) for RIC recipients, respectively. Donor toxicity was reduced relative to G-CSF mobilized related donors. This is the first multicenter trial to demonstrate that, as an alternative to G-CSF, plerixafor rapidly and safely mobilizes sufficient numbers of CD34+ cells from matched sibling donors for HCT. Engraftment was prompt, and outcomes in recipients were encouraging. This trial was registered at clinicaltrials.gov as #NCT01696461.
Conflict of interest statement
Conflict-of-interest disclosure: The authors declare no competing financial interests.
© 2019 by The American Society of Hematology.
Figures
Source: PubMed